Symbicort Turbuhaler 30/60 Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- Registration Number
- NCT01232348
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3643
Inclusion Criteria
- Patients treated with Symbicort for the first time due to bronchial asthma
Exclusion Criteria
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Adverse Events Range of 12 weeks
- Secondary Outcome Measures
Name Time Method The level of asthma control Range of 12 weeks The level of patient satisfaction with Symbicort Range of 12 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Symbicort Turbuhaler in managing bronchial asthma symptoms?
How does Symbicort Turbuhaler 30/60 compare to standard-of-care beta-agonists in asthma treatment outcomes?
Which biomarkers correlate with improved patient satisfaction in Symbicort-treated asthma populations?
What adverse drug reactions are associated with beta-stimulant use in Symbicort Turbuhaler 30/60?
Are there combination therapies involving Symbicort Turbuhaler that enhance asthma control in clinical practice?
Trial Locations
- Locations (1)
Research Site
🇯🇵Yamanashi, Japan